Sun Pharma said to be planning upgrades, new R&D facility at troubled Madhya Pradesh facility

pills

Sun Pharmaceutical, India’s largest generics maker, is reportedly looking to make a “significant investment” at the troubled facility in Madhya Pradesh the company inherited when it acquired Ranbaxy Laboratories for $4 billion.

The Dewas site in Madhya Pradesh is one of four manufacturing facilities that were banned by the FDA while they were operating under the Ranbaxy flag.

The improvements at the site by Sun are reported to include a new R&D facility, liveMint reported. Sun recently signed a deal with the Indian government to work towards eradicating malaria.

Sun officials have repeatedly said following the Ranbaxy buyout last year that as they integrate the two companies they would also upgrade the four Ranbaxy plants in India that made the FDA banned list for data integrity problems and other issues.

In May, Sun said that it would be looking for the FDA to reinspect at least one of the plants by the end of the year.

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

Branded drug sales in China could suffer in the short term as marketing activities for new meds are limited to reduce the risk of contagion.